Effect of Antiviral Therapy on Host Immune in Patients With Chronic Hepatitis B Virus(HBV) Infection

Not Applicable

Completed

• Conditions: HBeAg Positive Chronic Hepatitis B Infection
• Interventions: Drug: Telbivudine

• Registration Number: NCT01480492
• Lead Sponsor: Cz Li

Brief Summary

During hepatitis B virus(HBV) infection host immune plays important role.Recently there are many different antiviral therapy methods.Different antiviral therapy methods showed different effector.In order to investigate whether these antiviral therapy methods especially methods directly inhibit viral replication have some effect on host immune the investigators designed these study. The investigators want to observe the change of host immune during antiviral therapy in patients with chronic HBV infection, and analyze the relationship between these changes and the antiviral effector of these drugs.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01
• Primary Completion: 2011-10
• Study Completion: 2011-10
• Status Verified: 2011-11
• Study First Submitted: 2011-11-15
• Study First Submitted QC: 2011-11-28
• Last Update Submitted: 2011-11-28
• Study First Posted: 2011-11-29
• Last Update Posted: 2011-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
therapy	Telbivudine	-

Primary Outcome Measures

Name	Time	Method
change of programmed death-1(PD-1) level of patients with chronic HBV infection during therapy	base line-4 weeks-12 weeks-24 weeks-end of therapy

Secondary Outcome Measures

Name	Time	Method
Decline of hepatitis B e antigen (HBeAg) level	base line-4weeks-12weeks-24weeks-end of therapy

Trial Locations

Locations (1)

Changhai Hospital; 🇨🇳 Shanghai, Shanghai, China